FDA approves drugs from Vertex, Novo, Bristol Myers to wrap 2024
The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...
FDA approves injectable version of Bristol Myers Squibb's cancer drug Opdivo
The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's ...
Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors
Shares of Bristol Myers Squibb Co. BMY slumped 0.55% to $57.68 Friday, on what proved to be an all-around poor trading ...
FiercePharma5h
Bristol Myers celebrates 10 years of Opdivo with FDA approval for subcutaneous version
Almost exactly 10 years after the FDA’s initial FDA approval for Bristol Myers Squibb’s Opdivo as the first PD-1 inhibitor in ...
Decoding Bristol-Myers Squibb's Options Activity: What's the Big Picture?
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Bristol-Myers ...
bovnews2h
What’s Behind the 0.89% Gain in Bristol-Myers Squibb Co (BMY) Stock? Find Out Now!
Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $56.56 which represents a slight increase of $0.50 or 0.89% from the prior close of $56.06. The stock opened at $56.07 and ...
Bristol-Myers Squibb Stock: Clearly Undervalued, Excellent 2H24 Culminates In Opdivo 'Subcu' Approval
Bristol-Myers Squibb has rebounded strongly in 2024, driven by key drug approvals and positive financial performance. See why ...
Peering Into Bristol-Myers Squibb's Recent Short Interest
According to Benzinga Pro, Bristol-Myers Squibb's peer group average for short interest as a percentage of float is 4.30%, ...
Is Bristol-Myers Squibb Co. (BMY) the Best Stock for 10 Years?
We recently compiled a list of the Long-Term Stock Portfolio: Best Stocks for 10 Years. In this article, we are going to take ...
Bristol-Myers Squibb Will Handle The Patent Cliff And Is Still Undervalued
Bristol-Myers Squibb faces patent risks but has promising new drugs. Find out why BMY stock remains a "Buy" with strong ...
Bristol-Myers Squibb's Long-term Dividend Outlook appears Promising
Bristol-Myers Squibb Company ( NYSE:BMY) has announced that it will be increasing its dividend from last year's comparable ...
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors despite daily gains
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...